↓ Skip to main content

Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer

Overview of attention for article published in this source, August 2014
Altmetric Badge

Mentioned by

twitter
2 X users
wikipedia
5 Wikipedia pages

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
60 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer
Published by
John Wiley & Sons, Ltd, August 2014
DOI 10.1002/14651858.cd006945.pub3
Pubmed ID
Authors

Cheuk, Daniel KL, Chiang, Alan KS, Chan, Godfrey CF, Ha, Shau Yin

Abstract

Tumour lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Preliminary reports suggest that urate oxidase is effective in reducing serum uric acid, the build-up of which causes TLS. It is uncertain whether high-quality evidence exists to support its routine use in children with malignancies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 2%
Unknown 59 98%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 12 20%
Student > Ph. D. Student 9 15%
Student > Master 8 13%
Student > Bachelor 4 7%
Researcher 4 7%
Other 14 23%
Unknown 9 15%
Readers by discipline Count As %
Medicine and Dentistry 29 48%
Nursing and Health Professions 7 12%
Biochemistry, Genetics and Molecular Biology 3 5%
Sports and Recreations 3 5%
Agricultural and Biological Sciences 2 3%
Other 5 8%
Unknown 11 18%